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Disruption of Dag1 in Differentiated
Skeletal Muscle Reveals a Role
for Dystroglycan in Muscle Regeneration
troglycans [ and  subunits], sarcoglycans [, , , and
 subunits], and sarcospan). Disruption of this linkage,
due to mutations of dystrophin or the sarcoglycans,
causes sarcolemmal instability and contraction-induced
tears to the sarcolemma (Alderton and Steinhardt, 2000).
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analysis suggested that dystroglycan has important
roles outside of muscle, which cover a broad range ofSummary
biological inquiry (for review see Henry and Campbell,
1999). Generation of dystroglycan null mice indicatedStriated muscle-specific disruption of the dystrogly-
that dystroglycan is required for the formation ofcan (DAG1) gene results in loss of the dystrophin-
Reichert’s membrane during early embryonic develop-glycoprotein complex in differentiated muscle and a
ment, disruption of which causes embryonic lethalityremarkably mild muscular dystrophy with hypertrophy
(Williamson et al., 1997). Subsequent studies have dem-and without tissue fibrosis. We find that satellite cells,
onstrated that dystroglycan is required for the formationexpressing dystroglycan, support continued efficient
of the subendodermal basement membrane in embryoidregeneration of skeletal muscle along with transient
bodies (Henry and Campbell, 1998). Mice chimeric forexpression of dystroglycan in regenerating muscle fi-
dystroglycan expression in all tissues have been re-bers. We demonstrate a similar phenomenon of reex-
ported to develop severe muscular dystrophy (Cote etpression of functional dystroglycan in regenerating
al., 1999). Recently it has been demonstrated that tissue-muscle fibers in a mild form of human muscular dystro-
specific disruption of dystroglycan in the brain is suffi-phy caused by disruption of posttranslational dystro-
cient to cause neuronal migration errors that closelyglycan processing. Thus, maintenance of regenerative
resemble the brain abnormalities seen in congenitalcapacity by satellite cells expressing dystroglycan is
muscular dystrophy (Moore et al., 2002). Moreover, welikely responsible for mild disease progression in mice
have shown that mutations in glycosyltransferases
and possibly humans. Therefore, inadequate repair of
(POMGnT1, fukutin, and LARGE) result in posttransla-
skeletal muscle by satellite cells represents an impor- tional disruption of dystroglycan-ligand interactions in
tant mechanism affecting the pathogenesis of muscu- the skeletal muscle of patients with a severe phenotype
lar dystrophy. of congenital muscular dystrophy (Michele et al., 2002).
In order to better understand the function of dystrogly-
Introduction can in mature, differentiated skeletal muscle, we have
used the Cre-loxP system to specifically inactivate the
Muscular dystrophies are a diverse group of inherited dystroglycan gene in skeletal muscle using the muscle
disorders characterized by progressive muscle weak- creatine kinase (MCK) promoter in transgenic mice (Bru-
ness and wasting (Bushby, 2000; Cohn and Campbell, ning et al., 1998). Mice with skeletal muscle-specific
2000). The dystrophin-glycoprotein complex (DGC) is disruption of dystroglycan (MCK-DG null) develop myo-
a multisubunit complex comprised of peripheral and necrosis around 4–6 weeks of age, indicating that loss
integral membrane proteins, which links the cytoskele- of dystroglycan and accompanying disruption of the
ton to the extracellular matrix. The proteins that com- DGC at the sarcolemma alone is sufficient to cause
prise the DGC are the intracellular proteins (dystrophin muscular dystrophy. Given the previously demonstrated
and the syntrophins) and the sarcolemmal proteins (dys- findings in functionally dystroglycan null patients and
mice (Michele et al., 2002) we were surprised to find
that despite ongoing cycles of muscle degeneration,6 Correspondence: kevin-campbell@uiowa.edu
7 These authors contributed equally to this work. MCK-DG null mice with advanced age do not exhibit
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signs of fibrosis and fat replacement generally seen in
other mouse models of muscular dystrophy. Instead,
they present with a remarkably mild phenotype with
signs of efficient muscle regeneration and marked skele-
tal muscle hypertrophy similar to findings observed in
early stages of human and mouse models with muscular
dystrophy.
Here we find that dystroglycan is expressed in satellite
cells. During cycles of degeneration, satellite cells are
repetitively activated in MCK-DG null mice. Because
satellite cells have not been targeted by the MCK Cre
promoter, this activation leads to expression of dystro-
glycan and other components of the DGC in muscle
fibers undergoing regeneration. Our results reveal the
first in vivo evidence that self-renewing potential does
not necessarily decrease in aging mice undergoing re-
petitive cycles of de- and regeneration during the course
of muscular dystrophy. Our findings provide new in-
sights into the pathogenesis of muscular dystrophy by
demonstrating that perturbation of satellite cell function
leading to insufficient repair of skeletal muscle cells
represents a major pathogenetic mechanism in the
course of muscular dystrophy.
Results
Generation of Dystroglycan (lox) Mice
and Breeding Strategy
Dystroglycan (DG), the central component of the dys-
trophin-glycoprotein complex (DGC), is expressed in vir- Figure 1. Skeletal Muscle-Specific Disruption of Dystroglycan
tually every tissue in humans and other mammals. To (A) Immunohistochemical analysis reveals loss of - and -dystro-
glycan (DG, DG) at the sarcolemma of MCK-DG null mice. Arrowinvestigate selectively the role of dystroglycan expres-
marks dystroglycan in vascular smooth muscle.sion and function in striated muscle of the mouse, we
(B) Western blot analysis of skeletal muscle KCL-washed micro-have employed conditional gene inactivation using Cre-
somes shows almost complete loss of dystroglycan in MCK-DG null
loxP-mediated recombination (Gu et al., 1994). To this mice. In contrast, normal levels of dystroglycan expression can be
end, we generated a mouse bearing a “floxed” allele of observed in wild-type (wt), heterozygous dystroglycan null (DG/),
dystroglycan in which loxP sites were introduced flank- heterozygous floxed/dystroglycan null (L/), and homozygous
floxed (L/L) mice. Note that 1S calcium channel is normally ex-ing exon 2 of the mouse dystroglycan gene. Breeding of
pressed in all membrane preparations studied.DG (lox/) and MCK-Cre (/) mice resulted in double
(C) Absence of dystroglycan leads to perturbation of the DGC (DYS,heterozygous animals that were then bred with DG
dystrophin; -SG, -sarcoglycan; -SG, -sarcoglycan; -SG,
(lox/) mice to obtain DG (lox/lox):MCK-Cre offspring,
-sarcoglycan; -SG, -sarcoglycan; SSPN, sarcospan). Note that
that is, mice with a disruption of dystroglycan specifi- caveolin-3 (cav-3) and laminin 2 (LAM2) expression is not affected
cally in striated muscle (MCK-DG null). There was no by loss of dystroglycan.
(D) Hematoxylin- and eosin-stained sections of tibialis anterior mus-embryonic lethality, and these mice were obtained with
cle demonstrate hallmarks of muscular dystrophy in MCK-DG nullthe expected frequency of 12.5% for a trait requiring
mice at 6 weeks of age.two independent loci. Newborn MCK-DG null mice were
(E) MCK-DG null mice exhibit significant elevation of serum creatine
indistinguishable from their DG (lox/lox) and wild-type kinase (error bars represent SD).
littermates and grew normally. In a different breeding
strategy, we generated mice heterozygous for the floxed
gene and for the original dystroglycan knockout allele muscular junctions, suggesting that MCK-Cre either
might not be active in myonuclei associated with these(L/). These mice were then bred to MCK-Cre mice in
order to obtain MCK-Cre/L/ mice. However, no differ- sites or that dystroglycan half-life and turnover might
be different (not shown).ence in protein expression pattern as well as in phenotype
was observed between MCK-Cre/L/ and MCK-Cre/L/L
mice. RT-PCR showed loss of mRNA for dystroglycan MCK-DG Null Mice Show Disruption of the DGC
and Develop Muscular Dystrophyin MCK-DG null mice. Western blot analysis and immu-
nohistochemistry revealed loss of dystroglycan in skele- Immunohistochemical analysis from 6-week-old MCK-
DG null mice revealed that the absence of dystroglycantal muscle of MCK-DG null mice (Cre/L/L and Cre/L/)
and normal expression in wild-type, heterozygous dys- expression in skeletal muscle was accompanied by loss
of dystrophin, dystrobrevin, and the sarcoglycan-sar-troglycan null mice (L/), and homozygous floxed mice
(L/L) (Figure 1). Interestingly, dystroglycan staining was cospan complex (Figure 1). Interestingly, in MCK-DG null
mice, dystrophin sarcolemma localization varied fromsolely lost from the sarcolemma in skeletal muscle and
still preserved in myotendinous junctions and neuro- normal staining (e.g., tibialis) to reduced staining (e.g.,
Dystroglycan and Muscle Regeneration
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Table 1. Increased Muscle Weight in MCK-DG Null Mice
MCK-Cre MCK-DG Null
Quadricepsa 300.5  10.3 620.5  11.7b
Soleus 31.4  1.2 36.4  2.1
EDL 22.2  1.1 45.3  1.5b
Gastroc. 460.5  11.7 922.8  9.8b
Triceps 280  5 420  20b
Heart 190.4  12.1 290.4  26.6b
Body weightc 40.32  1.90 47.24  1.30b
Male littermate mice carrying only the MCK-Cre transgene and
MCK-DG null wet muscle weights. Mean volumes were compiled
from five mice of each genotype at 15 months of age. In contrast to
MCK-Cre, MCK-DG null mice show widespread increase in muscle
weight.
a Muscle weight in milligrams; mean  SD (n  5)
b Statistically significant p 	 0.001.
c Body weight in grams; mean  SD (n  5)
Figure 2. Gross and Histological Analysis of Skeletal Muscle Hyper-
ness confirmed the observed increase in wet muscletrophy
weight (Figure 2). Fiber diameter of quadriceps and so-
MCK-DG null mice are larger (A) and the musculature of the hindlimb
leus muscle in 18-month-old MCK transgenic mice re-is increased in size (B). Note the significant increase in thickness
vealed a mean value of 35  8 
m and 23  5 
m,and increased muscle fiber diameter in diaphragm of MCK-DG null
mice (C and D). Bar represents 350 
m. respectively, as compared to 79  15 
m and 56  18

m in quadriceps and soleus muscle of 18-month-old
MCK-DG-null mice (p 	 0.0001). Moreover, up to 95%
quadriceps) depending on muscle group. The immuno- of the muscle fibers exhibited centrally located nuclei,
fluorescent data were confirmed by Western blot studies indicating that regeneration had occurred in these fibers.
of KCL-washed microsomal fractions (data not shown).
In addition, neuronal nitric oxide synthase and 1-syn- Synchronized Reexpression of Dystroglycan
trophin were also absent from the sarcolemma in MCK- during Regenerative Cycles
DG null mice (data not shown). Expression of laminin The unexpected finding of skeletal muscle hypertrophy
2 was normal in MCK-DG null mice, which can most and morphological signs of muscle regeneration even
likely be explained by normal sarcolemmal expression in 15- to 18-month-old MCK-DG null mice prompted
levels of 7 integrin (data not shown), which serves as us to more closely investigate this phenomenon. One
an additional receptor for laminin 2 in skeletal muscle. interesting observation we made during our analysis of
Histological studies of various skeletal muscles, in- MCK-DG null mice was that clusters of dystroglycan-
cluding quadriceps, gastrocnemius, tibialis anterior, bi- positive muscle fibers were consistently present in older
ceps, gluteus maximus, and diaphragm, displayed his- mice. Therefore, we studied expression levels of dys-
tological hallmarks of muscular dystrophy such as troglycan in MCK-DG null mice at various ages using
myonecrosis, central nucleation, and variation of fiber an immunohistochemical approach. Remarkably, dys-
size in MCK-DG null mice at around 6 weeks of age. troglycan was expressed at normal levels in newborn
Furthermore, significant elevation of serum creatine ki- MCK-DG null mice (Figure 3A). By around 4 weeks of
nase was observed in these mice (Figure 1). age, dystroglycan expression was nearly absent from
the sarcolemma (fewer than 5% fibers were positive).
In contrast, analysis of dystroglycan expression in MCK-MCK-DG Null Mice Develop Significant Skeletal
Muscle Hypertrophy with Age DG null mice at numerous intervals between 10 weeks
and 18 months of age revealed muscle fiber groupsAs MCK-DG null mice aged, we observed an interesting
phenomenon. In marked contrast to other models of expressing dystroglycan with a frequency of dystrogly-
can-positive fibers of around 40% and 54%, respectivelymuscular dystrophy such as the dystrophin-deficient
mdx mice or the sarcoglycan null mice, which show (Figure 3A). Dystroglycan-positive clusters were present
only after the onset of the dystrophic process, whichsignificant muscle atrophy at 12–18 months of life, MCK-
DG null mice developed substantial hypertrophy of the began at about 6 weeks of age. These results led us
to hypothesize that dystroglycan might be reexpressedskeletal muscle. As shown in Figure 2 and Table 1, 15-
month-old MCK-DG null mice were larger than littermate during regenerative cycles caused by the ongoing dys-
trophic process and that activated satellite cells or othercontrols only carrying the Cre transgene. Similar results
were observed when MCK-DG null mice were compared myogenic precursor cells, which are not targeted by
the MCK-Cre promoter, might initiate the expression ofto age-matched homozygous dystroglycan-floxed mice
(data not shown). Determination of wet muscle weights dystroglycan during the course of regeneration.
Consequently, we analyzed frozen crosssections ofshowed widespread increase of muscle mass, particu-
larly in the quadriceps and gastrocnemius muscles, skeletal muscle from wild-type and MCK-DG null mice
for satellite cell expression of dystroglycan and M-cadh-where the weight doubled (Table 1). Histological evalua-
tion of muscle fibers as well as the full diaphragm thick- erin, a cell adhesion molecule that has been reported to
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Figure 4. Reexpression of Dystroglycan in Regenerating Fibers of
MCK-DG Null Mice
(A) Challenging muscle fibers with cardiotoxin leads to synchronized
reexpression of dystroglycan in MCK-DG null mice at 4 and 14
days of toxin injection. Actively regenerating fibers are positive for
neonatal myosin (top right, green color). In contrast, 28 days after
administration of cardiotoxin, expression of dystroglycan was mark-Figure 3. Dystroglycan Is Expressed in Satellite Cells
edly reduced, indicating that MCK-Cre-mediated recombination has(A) Analysis of dystroglycan expression at various ages in MCK-
again occurred in these muscle fibers (bottom right). Bar representsDG null mice. Interestingly, dystroglycan is normally expressed in
50 
m.newborn skeletal muscle. In contrast, at 4 weeks of age, dystrogly-
(B) Exposure of single legs from MCK-DG null mice to 25 Gy irradia-can is nearly absent from the sarcolemma. Subsequently, MCK-
tion (rad) leads to almost complete loss of dystroglycan expressionDG null mice develop muscular dystrophy with ongoing cycles of
6 weeks and 4 months after irradiation. Morphological analysis ofnecrosis and regeneration. After onset of the dystrophic process,
skeletal muscle demonstrates the development of a more severeclusters of dystroglycan-positive muscle fibers are observed in
dystrophic phenotype with endomysial fibrosis and adipose tissueMCK-DG null mice between 10 weeks and 18 months of age (anti-
replacement. Bar represents 50 
m.body AP 83 against -dystroglycan).
(B) Expression of dystroglycan in satellite cells of wild-type and
MCK-DG null mice. Double labeling with M-cadherin reveals en- cle. Remarkably, dystroglycan was strongly expressed
hanced membrane staining of the satellite cell toward the cytoplasm in regenerating fibers 4 days after cardiotoxin injection
of the myofiber, whereas dystroglycan expression seems to be en-
(Figure 4A), and strong sarcolemmal expression of dys-hanced toward the basal lamina. The merged image including DAPI
troglycan was still observed 14 days after injection ofdemonstrates the single nucleus of the satellite cell.
cardiotoxin. In contrast, 28 days after administration of
cardiotoxin, expression of dystroglycan was markedly
be expressed in quiescent, activated, and proliferating reduced in MCK-DG null muscle, indicating that MCK-
satellite cells (Irintchev et al., 1994). Figure 3B reveals Cre-mediated recombination had again occurred in
dystroglycan expression in satellite cells of MCK-DG these muscle fibers (Figure 4A). These data supported
null mice, with an enhanced membrane labeling toward our hypothesis that activated satellite cells during mus-
the basal lamina of the parent muscle fiber. Double label- cle regeneration led to reexpression of dystroglycan in
ing with M-cadherin, which has enhanced staining at dystrophic muscle of MCK-DG null mice.
sites of contact between satellite cells and the parent In order to more firmly establish that satellite cells are
muscle fiber, and nuclear staining using DAPI identified responsible for the dystroglycan staining observed in
the dystroglycan-positive cell as a satellite cell (Figure MCK-DG null mice, we exposed single legs of 4-month-
3B). Moreover, in vitro isolation of satellite cells showed old mice to 18 Gy and 25 Gy of irradiation to inactivate
positive staining for dystroglycan in myoblasts of homo- the satellite cell population. Analysis of dystroglycan
zygous floxed (L/L) and MCK-DG null mice and loss of expression 3 weeks, 6 weeks, and 4 months after irradia-
dystroglycan in differentiated myotubes of MCK-DG null tion showed complete absence of dystroglycan at the
mice (not shown). sarcolemma of MCK-DG null mice. Moreover, morpho-
Given these data, we sought to induce more extensive logical analysis exhibited a considerably more severe
and synchronized regeneration in wild-type and MCK- dystrophic phenotype with endomysial fibrosis and adi-
pose tissue replacement (Figure 4B).DG null mice by injecting cardiotoxin into the calf mus-
Dystroglycan and Muscle Regeneration
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Figure 5. Characterization of the DGC in Regenerating Fibers of Various Muscular Dystrophy Mouse Models
Analysis of DGC expression 4 days after cardiotoxin injection reveals normal expression levels for -dystroglycan (-DG), -sarcoglycan
(-SG), -sarcoglycan (-SG), utrophin (UTR), and dystrophin (DYS) in MCK-DG null mice. In contrast, upregulation of utrophin compensates
in part for the loss of dystrophin during the regeneration process in mdx mice (middle), as shown by almost normal expression levels for
dystroglycan and sarcoglycan. However, some mdx fibers (asterisks) express reduced amounts of dystroglycan and sarcoglycan. Sgcd null
mice lack upregulation of a protein to compensate for -sarcoglycan and display no expression for - and -sarcoglycan in regenerating
fibers. Interestingly, dystrophin expression at the sarcolemma is reduced in actively regenerating muscle fibers. Bar represents 50 
m.
Induction of regeneration in 15-month-old MCK-DG null, mdx, and -sarcoglycan null mice (Sgcd null) by administration of cardiotoxin (right).
Note the impaired regeneration capacity of mdx and -sarcoglycan null mice 4 days and 14 days after cardiotoxin challenge as compared to
the effective regeneration in MCK-DG null mice. Bar represents 100 
m.
MCK-DG Null Mice Maintain Their Regenerating perturbed expression of the DGC, while regenerating
myofibers in MCK-DG null mice expressed relatively nor-Capacity in Contrast to mdx and Sarcoglycan
Null Mice mal DGC.
In order to compare the regenerative capacity of MCK-In order to evaluate whether the dystrophin-glycoprotein
complex might have an impact on muscle regeneration, DG null mice to dystrophin-deficient mdx mice and sarco-
glycan null mice, we exposed 4-month-old and 15-we studied by immunohistochemistry the expression of
DGC components in 4-month-old wild-type, MCK-DG month-old mice to calf injections of cardiotoxin and ana-
lyzed the phenotype 4 days and 14 days after injectionnull, mdx, and -sarcoglycan null mice 4 days after
cardiotoxin challenge. MCK-DG null mice showed ex- of the toxin. At 4 months of age, wild-type and MCK-
DG null mice as well as mdx and -sarcoglycan null micepression levels that were similar to wild-type muscle of
-dystroglycan, -sarcoglycan, -sarcoglycan, utrophin, showed signs of effective regeneration, as assessed
by the presence of small rounded muscle fibers withand dystrophin during regeneration (Figure 5). In con-
trast, expression levels of DGC components were mark- centrally located nuclei, a basophilic cytoplasm, and
neonatal myosin immunoreactivity 4 days after injectionedly abnormal in mdx and -sarcoglycan null mice.
Although upregulation of utrophin in actively regener- (data not shown). Fourteen days after cardiotoxin injec-
tion, muscle architecture was largely restored, as dem-ating muscle fibers does seem to partially compensate
for the absence of dystrophin in mdx mice, expression onstrated by the presence of normal diameter and cen-
trally nucleated myofibers in MCK-DG null, mdx, andlevels for -dystroglycan and the sarcoglycans de-
crease shortly (about 7–10 days) after the acute phase of -sarcoglycan null mice (data not shown). In marked
contrast, cardiotoxin challenge in 15-month-old miceregeneration (Figure 5). Mice deficient for -sarcoglycan
apparently lack upregulation of a compensatory protein exhibited a difference between MCK-DG null mice on
the one hand and mdx and -sarcoglycan null mice onfor the missing sarcoglycan; thus, no sarcoglycan ex-
pression was observed during the acute phase of mus- the other. MCK-DG null mice showed signs of effective
regeneration 4 days after cardiotoxin injection, whereascle regeneration. Interestingly, analysis of dystrophin
expression revealed that sarcolemmal localization of mdx mice and -sarcoglycan null mice responded only
poorly to the cardiotoxin-induced regeneration chal-dystrophin is reduced in muscle fibers of -sarcoglycan
null mice 4 days after cardiotoxin injection. These data lenge (Figure 5). Interestingly, the regenerative response
was less efficient in sarcoglycan null mice compared toindicate that the regeneration process in mdx and sar-
coglycan null mice led to repopulation by myofibers with mdx mice. The histological observations were confirmed
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exhibited extensive skeletal muscle hypertrophy but did
not develop the devastating histopathology observed
in mdx and/or -sarcoglycan null mice. Despite the rela-
tively mild changes in 18-month-old MCK-DG null mice,
elevation of serum creatine kinase levels and histologi-
cal analysis of serial sections of various muscle types
(n  6 mice) confirmed ongoing cell necrosis, indicating
the continuation of the dystrophic process.
Transient Reexpression of Dystroglycan
in Regenerating Fibers of Human
Limb-Girdle Muscular Dystrophy
Figure 6. Comparison of Muscular Dystrophy in 18-Month-Old Mice Recent evidence shows that altered -dystroglycan ex-
The capability of MCK-DG null mice to efficiently maintain skeletal pression in recently described forms of limb-girdle mus-
muscle regeneration not only leads to significant muscle hypertro- cular dystrophy does not necessarily lead to a severe
phy, but also prevents the development of severe dystrophic alter- phenotype, and a subset of these patients presents with
ations as observed in mdx and Sgcd null mice. Bars represent 50 marked muscle hypertrophy (Brockington et al., 2001).

m and 120 
m, in the upper and lower right panels, respectively.
Thus, we started to analyze dystroglycan expression in
patients with milder forms of muscular dystrophy.
Interestingly, we find that glycosylated dystroglycanby counting of neonatal myosin-positive fibers as a
is reexpressed in regenerating fibers in three patientsmarker for acute regeneration in 300 fibers randomly
with a mild form of limb-girdle muscular dystrophychosen from 5–10 regions per toxin-challenged muscle
caused by disruption of posttranslational dystroglycanin wild-type, MCK-DG null, mdx, and sarcoglycan null
processing (Figure 7A). In marked contrast, no residualmice (n  4, each group). The quantification demon-
glycosylated dystroglycan is expressed in regeneratingstrated similar numbers of neonatal myosin-positive fi-
fibers of patients with Fukuyama muscular dystrophybers in wild-type and MCK-DG null mice (230  25 and
and muscle-eye-brain disease, which present with a se-220  32, respectively) and dramatically fewer neonatal
vere clinical phenotype (D.E.M. and K.P.C., unpublishedmyosin-positive fibers in mdx and -sarcoglycan null
data). Biochemical characterization of dystroglycan ex-mice (109  14 and 62  9, respectively, p 	 0.0002).
pression in one of these patients with mild limb-girdleFourteen days after cardiotoxin injection, MCK-DG
muscular dystrophy revealed that glycosylated -dys-null mice exhibited a nearly full restoration of the chal-
troglycan is not significantly detected while the corelenged muscle fiber groups, whereas mdx mice and
protein shows a shift in apparent molecular weight ofsarcoglycan null mice still had regions of hypercellular
about 55 kDa (Figure 7B). No laminin binding was de-myonecrotic response, indicating impaired regeneration
tected in the hypoglycosylated dystroglycan from thecapacity (Figure 5). Moreover, impaired muscle regener-
patient. Moreover, comparison of laminin binding activ-ation in mdx and -sarcoglycan null mice was eventually
ity of the patient to MCK-DG null mice shows similaraccompanied by extensive replacement of muscle by
reductions of total high-affinity laminin binding activityadipose tissue 4 weeks after cardiotoxin injection (data
in WGA-enriched muscle homogenates from bothnot shown).
sources. This indicates considerable loss of dystrogly-In order to finally demonstrate that dystroglycan has
can ligand binding activity in both muscle samples (Fig-an essential role in the biological function of satellite
ure 7C).cells in vivo, we studied the effect of cardiotoxin on
skeletal muscle regeneration in mice lacking dystrogly-
can at the sarcolemma of skeletal muscle as well as in Discussion
satellite cells using MORE-DG null mice. MORE-DG null
mice lack dystroglycan in all tissues in the embryo. How- Several forms of muscular dystrophy caused by mutations
of components of the DGC have been identified duringever, dystroglycan is still expressed in extraembryonic
membranes to circumvent embryonic lethality. Interest- the past two decades. However, we lack a clear under-
standing of the pathogenetic mechanism(s) responsibleingly, cardiotoxin challenge in MORE-DG null mice (2
weeks of age) revealed not only lack of reexpression of for the severe progressive and devastating course of
these disorders. Current hypotheses developed throughdystroglycan but also severely impaired regenerative
response 4 and 7 days after toxin injection (see Supple- many years of research suggest two main biological
cascades involved in the dystrophic disease process.mental Figure S2 at http://www.cell.com/cgi/content/
full/110/5/639/DC1), demonstrating that dystroglycan First, the DGC plays an essential role in protecting the
sarcolemma against muscle contraction-induced injury,expression in satellite cells is essential for the regenerat-
ing capacity in skeletal muscle. and perturbation of the DGC causes sarcolemmal insta-
bility and structural damage subsequently leading toMorphological comparison of MCK-DG null, mdx, and
-sarcoglycan mice at 18 months of age (n  6 for each increased calcium influx followed by muscle cell death.
Second, while skeletal muscle seems capable of effi-group), which have not been challenged by any toxin
injections, demonstrated the development of significant ciently repairing itself during the early phase of the dis-
ease, it is believed that the ongoing stimulus and activa-endomysial fibrosis and extensive replacement of mus-
cle by adipose tissue in mdx and -sarcoglycan null tion of the repair mechanism eventually exhaust the
satellite cell pool. Consequently, failure of the myogenicmice (Figure 6). In marked contrast, MCK-DG null mice
Dystroglycan and Muscle Regeneration
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and stability of the sarcolemma in skeletal muscle. How-
ever, our data elaborate on the second paradigm. We
find that dystroglycan plays an essential role in satellite
cell function by demonstrating that muscle-regenerating
capacity can be sustained until senescence despite re-
petitive activation of degeneration/regeneration cycles,
thereby preventing the development of severe tissue
fibrosis and fat replacement. Thus, dysfunction of the
satellite cell population leading to impairment of the
repair mechanism in skeletal muscle represents a key
mechanism in the pathogenesis of muscular dystrophy.
Absence of Dystroglycan Leads to Disruption of
the DGC and Development of Muscular Dystrophy
Dystroglycan is a central component of the DGC in skel-
etal muscle. As our current data demonstrate, dystrogly-
can plays a key role in the expression of the DGC and
in maintaining normal muscle function. Mice with tissue-
specific ablation of dystroglycan show disruption of the
DGC and develop muscular dystrophy. In vivo restora-
tion of dystroglycan via adenovirus injection into skeletal
muscle leads to expression of dystroglycan at the sarco-
lemma of MCK-DG null mice and consequently prevents
the development of muscular dystrophy (data not
shown). MCK-DG null mice show normal expression of
laminin 2 and no perturbation of the basement mem-
brane as revealed by electron microscopy studies (data
not shown). Importantly, MCK-DG null mice show a spe-
cific absence of dystroglycan at the sarcolemma, while
expression is still preserved in other muscle structures
such as neuromuscular junctions and myotendinous
junctions as well as vascular smooth muscle and periph-
eral nerve. Numerous studies have demonstrated alter-
ations of neuromuscular junctions and myotendinous
junctions in dystrophin-deficient mdx mice (for review
see Winder, 1997). Moreover, recent studies have shown
that alterations of vascular smooth muscle can have
an impact on the severity of the dystrophic process in
mouse models deficient for - or -sarcoglycan (Cohn
and Campbell, 2000). In contrast, the development of
muscular dystrophy in MCK-DG null mice can be attrib-
uted solely to the loss of dystroglycan at the sarco-
lemma, emphasizing the essential role of dystroglycan
Figure 7. Loss of Fully Glycosylated -Dystroglycan (IIH6) in a Mild for muscle function and stability.
Form of Limb-Girdle Muscular Dystrophy
(A) Residual glycosylated -dystroglycan can be detected in regen- Dystroglycan Is Expressed in Satellite Cells
erating fibers labeled with embryonic myosin. Similar results were and Regenerating Muscle Fibers
obtained in the additional patients.
of MCK-DG Null Mice(B) Western blots and laminin overlay (OL) of WGA-enriched homog-
Studies in dystroglycan chimeric mice (Cote et al., 1999)enates of the patient’s muscle biopsy. Glycosylated -dystroglycan
showed that these mice develop severe muscular dys-is not significantly detected, and the core protein shows a shift in
apparent molecular weight of about 55 kDa. No laminin binding was trophy with increasing age with remarkable tissue fibro-
detected in the hypoglycosylated dystroglycan from the patient. sis and fat replacement. In addition, patients with abnor-
(C) Similar reduction of total high-affinity laminin binding activity in mal dystroglycan formation due to posttranslational
WGA-enriched homogenates of the limb-girdle muscular dystrophy
disruption of dystroglycan-ligand interaction presentpatient muscle biopsy and WGA-enriched homogenates of MCK-
with severe muscular dystrophy (Michele et al., 2002).DG null mice.
To our surprise, MCK-DG null mice developed a mild
phenotype with significant skeletal muscle hypertrophy
with age instead of the expected severe dystrophic fea-satellite cells to maintain muscle regeneration ultimately
leads to severe fibrosis and adipose tissue replacement tures such as tissue fibrosis and replacement of muscle
by adipose tissue. Interestingly, we observed synchro-(Cossu and Mavilio, 2000; Heslop et al., 2000), a process
that has not been attributed to any physiological function nized reexpression of dystroglycan in MCK-DG null mice
when they were challenged to regenerate muscle fibersof the DGC. The current manuscript reveals that dystrogly-
can and the DGC are indeed essential for the protection by intramuscular injection of cardiotoxin. Thus, we hy-
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pothesized that dystroglycan might be expressed in sat- muscle fibers. This partially compensates for the loss
of dystrophin and leads to increased amounts of dys-ellite cells, which are not targeted by the MCK-Cre-
driven promoter and that the satellite cell response to troglycan and sarcoglycan protein expression in these
fibers as compared to muscle fibers, which do not ex-muscle injury was responsible for repopulation by tran-
siently dystroglycan-positive myofibers. hibit signs of muscle regeneration and have perturbed
expression of the DGC (Ervasti et al., 1990; currentHere we were able to demonstrate in vivo and in vitro
that dystroglycan is indeed expressed in wild-type satel- manuscript). In contrast, mice deficient for -sarcogly-
can lack upregulation of a sarcoglycan-compensatorylite cells. Our current animal model exhibits a specific
disruption of skeletal muscle dystroglycan at the sarco- protein during their regeneration process. The observed
differences might explain the milder morphological phe-lemma. Hence, it provides a unique tool to study dys-
troglycan expression in other cells present in skeletal notype observed in mdx mice during their first year of life
as compared to -sarcoglycan null mice, which developmuscle that are not targeted by the MCK promoter.
Interestingly, we show that dystroglycan expression in severe fibrosis and adipose tissue replacement during
the first 9 months of life. However, it is interesting to notesatellite cells is enriched at the membrane site toward
the basal lamina of the surrounding muscle fiber. This that initial utrophin upregulation during regeneration in
mdx mice is not sufficient to prevent the development offinding suggests a role for dystroglycan in the attach-
ment and/or stability of satellite cells between the basal fibrosis later in life. Thus, our data together with previous
reports of dystrophin expression in satellite cells (Mus-lamina and the sarcolemma of their associated myofiber.
This may have an important impact on satellite cell func- sini et al., 1995; Kong and Anderson, 2001) suggest a
direct role of the DGC in satellite cell function and muscletion during regeneration.
In order to further support our hypothesis that the repair. Experiments in our laboratory are currently under
way to specifically characterize the expression patternsatellite response to muscle injury was responsible for
repopulation of dystroglycan-positive cells, we used  of DGC components in satellite cells in order to further
delineate the role of the DGC in muscle regeneration.irradiation to render satellite cells incapable of prolifera-
tion. Indeed, irradiation of satellite cells in 4-month-old
MCK-DG null mice resulted eventually in complete loss Transient Reexpression of Dystroglycan
of dystroglycan at the sarcolemma of skeletal muscle in Regenerating Fibers of Human Limb-Girdle
as well as an increased amount of fat and fibrotic tissue Muscular Dystrophy
replacement. Recent studies have shown that abnormal expression of
dystroglycan in skeletal muscle due to posttranslational
defects leads to several forms of human muscular dys-MCK-DG Null Mice Maintain
Regeneration Capacity trophy (Brockington et al., 2001; Michele et al., 2002).
Interestingly although most of the patients exhibit se-MCK-DG null mice represent an in vivo animal model
that maintains its regenerating capacity until senes- vere congenital/limb-girdle forms of muscular dystro-
phy, a subset of these patients present with a mildercence despite ongoing degeneration/regeneration cy-
cles in the course of muscular dystrophy. Even induction phenotype mostly characterized by skeletal muscle hy-
pertrophy (Brockington et al., 2001). Here we report dataof regeneration by administration of cardiotoxin into 15-
month-old MCK-DG null mice demonstrated efficient from three patients with mild human muscular dystrophy
and posttranslational functional disruption of dystrogly-regeneration of the challenged muscle fibers. The es-
sential biological role for dystroglycan in satellite cell can, displaying transient reexpression of normally pro-
cessed dystroglycan in regenerating muscle fibers. Wefunction in muscle regeneration is further substantiated
by the severely impaired regeneration response to are currently in the process of screening muscle biop-
sies from patients with mild muscular dystrophy, musclecardiotoxin challenge in MORE-DG null mice (R.B. and
K.P.C., unpublished data), which lack dystroglycan in hypertrophy, and abnormal dystroglycan expression in
order to more firmly establish the correlation betweensatellite cells and the sarcolemma of skeletal muscle.
Moreover, this idea would also explain why chimeric transient reexpression of dystroglycan in regenerating
fibers and mild clinical phenotype. The findings of thesemice for dystroglycan exhibit a more severe dystrophic
phenotype in skeletal muscle as described by Cote et patients described in the current manuscript represent
a phenomenon of transient reexpression of functionalal. (1999).
In marked contrast to MCK-DG null mice, which devel- dystroglycan from activated satellite cells similar to that
seen in MCK-DG null mice. These findings are in markedop significant skeletal muscle hypertrophy, old dys-
trophin-deficient mdx mice and mice deficient for contrast to Fukuyama congenital muscular dystrophy
and muscle-eye-brain disease patients, who exhibit-sarcoglycan exhibit severe endomysial fibrosis and
adipose tissue replacement in skeletal muscle. Analysis complete loss of dystroglycan posttranslational modifi-
cation but do not show expression of fully processedof DGC components in MCK-DG null, mdx, and -sar-
coglycan mice in regenerating muscle fibers demon- dystroglycan in regenerating fibers and have a more
severe dystrophic phenotype and more severe diseasestrated that satellite cells of mdx and -sarcoglycan
mice respond to the injury by repopulating the injured progression (D.E.M. and K.P.C., unpublished data). In
addition to the known proteins that effect dystroglycanskeletal muscle with myofibers defective in the expres-
sion of DGC components. MCK-DG null mice, on the glycosylation, fukutin, POMGnT-1, and LARGE, the hu-
man data presented here (Figure 7) suggest that addi-other hand, regenerate muscle fibers with an intact DGC.
In this regard it is interesting to note that mdx mice tional proteins may participate in functional modification
of dystroglycan. The data further suggest that some ofshow upregulation of utrophin in actively regenerating
Dystroglycan and Muscle Regeneration
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Soriano, 2000). The heterozygous mice Dag1/ carrying Mox2 Crethese proteins may be differentially expressed during
transgene (Cre/Dag1/) were than bred with Dag1lox/lox mice,myofiber regeneration. In future experiments, it will be
and heterozygous mice for Dag1lox/ carrying the Mox2 Cre (Cre/important to define both the temporal and spatial ex-
Dag1lox/) transgene were obtained. In an alternative breeding
pression of the components of this enzymatic pathway strategy, we bred heterozygous mice Dag1lox/ carrying the Mox2
in order to better delineate the pathogenesis of a variety Cre transgene (Cre/Dag1lox/) with Dag1lox/ mice to obtain Cre/
Dag1lox/ and homozygous mice for Dag1lox carrying the Mox2of human muscular dystrophies by understanding the
Cre transgene(Cre/Dag1lox/lox). Cre/Dag1lox/lox and Cre/Dag1lox/effect of the mutant protein on regenerative capacity
mice (MORE-DG mice) were viable, and the analysis of skeletalof muscle. Other target tissues with potential clinical
muscle revealed complete loss of dystroglycan (R.B. and K.P.C.,involvement may also be identified.
unpublished data). MORE mice were generously supplied from Drs.
Taken together, our data suggest that perturbation of Soriano and Tallquist.
satellite cell function and insufficient ability to repair
skeletal muscle cells represents a major mechanistic Histology and Immunohistochemistry
modifier in the pathogenesis of muscular dystrophy. Histopathological studies were performed as described before
Moreover, maintenance of regenerative capacity by sat- (Coral-Vazquez et al., 1999; Durbeej et al., 2000). Polyclonal antibod-
ies against -dystroglycan (rabbit 83), -sarcoglycan (rabbit 98),ellite cells expressing dystroglycan may be responsible
-sarcoglycan (goat 26), -sarcoglycan (rabbit 214), sarcospan (rab-for mild disease progression in mice and humans, which
bit 256), dystrophin (rabbit 31), and utrophin (rabbit 56) were de-opens up a new avenue of research involving the role
scribed previously (Durbeej et al., 2000). Polyclonal antibodies
of dystroglycan and associated proteins in muscle re- against -1 syntrophin (kind gift of Dr. Stanley Froehner), dystro-
generation capacity and its relationship to human mus- brevin (kind gift of Dr. Joshua Sanes), and laminin 2 (kind gift
cle disease. As various studies promote myogenic stem of Dr. Peter Yurchenko) were used for immunohistochemistry and
Western blot experiments. Monoclonal antibody against -dystro-cells as a therapeutic option for primary myopathies
glycan (IIH6) was described previously (Ervasti et al., 1990). Mono-such as muscular dystrophy (Ferrari et al., 1998; Gussoni
clonal antibody against neonatal myosin (Novocastra) and goat-et al., 1999; Cossu and Mavilio, 2000), our current data
polyclonal antibody against M-cadherin (Santa Cruz) were used for
represent unequivocal evidence that maintenance of immunohistochemistry. Immunohistochemical staining of satellite
self-renewing potential of skeletal muscle can largely cells was performed on frozen sections fixed in 4% paraformalde-
prevent the development of severe dystrophic alter- hyde, then washed in PBS containing 0.3% Triton X for 15 min
and subsequently blocked with 5% bovine serum albumin. Fiberations such as tissue fibrosis and fat replacement. Thus,
diameter was determined by measuring the shortest axis for allfuture efforts should be directed toward identifying ways
fibers within a crosssection to the nearest 10 
m counting a totalto maintain muscle regeneration capacity.
of 200 fibers of 5–10 randomly chosen regions within the quadriceps
and soleus muscle of 18-month-old MCK and MCK-DG-null mice
Experimental Procedures (n 4). These data were analyzed statistically using Student’s t test.
Generation of Floxed Dystroglycan Mice
RT-PCRA floxed dystoglycan targeting construct was generated by first
Total RNA was isolated from skeletal muscle tissue of wild-typeinserting a BamHI-SalI fragment from the intron of the mouse DG
and MCK-DG null mice using RNAzolB (Tel-Test) according to thegene 5 of a floxed PGK-neo expression cassette (Potocnik et al.,
manufacturer’s specification. Gene-specific sense primer (5-GCT2000). Subsequently, a HSV-tk cassette was added to this construct.
CATTTCGAGTGAGCATTCC-3) and antisense primer (5-CTAGTTNext, a SalI to EcoRV fragment containing the entirety of exon 2
TCCAGGACAGGAGA-3) were designed to anneal to the sequenceswas inserted 3 of the PGK-neo cassette. Finally, an EcoRV to NotI
in exon 1 and exon 2, respectively, which allow differentiation be-fragment bearing a loxP site (in the same orientation as those on
tween amplification of cDNA and potential contaminating genomicthe floxed neo cassette) at its 5 end was blunt-end ligated to the
DNA. Reverse transcription and PCR were performed with Super-EcoRV site of the genomic fragment containing exon 2 and, using
Script One Step RT-PCR with PLATINUM Taq (GIBCO-BRL) ac-a NotI/KpnI adaptor, was placed into the final targeting plasmid
cording to the manufacturer’s protocol, and the amplified DNA wasnamed DG-floxtk. Taken together, this construct results in the inser-
separated by 2% agarose gel electrophoresis.tion of a floxed neo cassette at the SalI site in the intron 5 of exon
2 and a loxP site at an EcoRV site 3 of exon 2, at a distance from
the polyadenylation signal sequence. DG-floxtk was electroporated Immunoblot Analysis
Proteins were resolved by SDS-polyacrylamide gel electrophoresisinto R1 ES cells and clones were screened by Southern blot with
external probe A (see Supplemental Figure S1 at http://www.cell. on 3%–15% linear gradient gels and transferred to nitrocellulose
membranes. Immunoblot analysis was performed as previously de-com/cgi/content/full/110/5/639/DC1). Positive clones were re-
screened with Probe B (see Supplemental Figure S1) to ensure that scribed (Durbeej et al., 2000) with the addition of 5 nM EDTA to the
homogenizing buffer. Laminin overlay and binding activity experi-the 3 loxP site was intact. We were unsuccessful at deleting the
neo marker in vitro by transfection with a Cre expression plasmid; ments have been described previously (Michele et al., 2002).
all recombinants lost exon 2 as well as neo. However, we do not
believe that the intronic PGK-neo expression cassette interferes Cardiotoxin Experiments
with expression of DG because there are no overt phenotypic abnor- All studies were performed in accordance with the guidelines of the
malities in homozygous DG-flox mice, and the levels of DG protein animal care facility at the University of Iowa. One hundred microliters
in skeletal muscle of those mice are similar to wild-type controls of 10 
M cardiotoxin (purified from the venom of Naja nigricollis
(data not shown). Targeted R1 ES cell clones were injected into snake; Sigma) was injected intramuscularly (Garry et al., 2000). In-
C57Bl6 host blastocysts to generate chimeric animals. Germline jected gastrocnemius was examined at 4, 7, 14, 21, and 28 days
transmission of the floxed DG allele was established by Southern after injection. For each experiment, 3 to 6 wild-type, MCK-DG null,
blot and PCR screening of agouti offspring. Mice bearing the floxed mdx, -sarcoglycan null mice were used. In addition, cardiotoxin
DG allele were mated to the MCK-Cre mice (Bruning et al., 2000) was injected into two MORE DG null mice, which lack dystroglycan in
as described in the Results section. all tissues including satellite cells and the -sarcolemma of skeletal
muscle. Quantification of neonatal myosin-positive fibers in wild-
type, MCK-DG null, mdx, and sarcoglycan null mice after cardiotoxinGeneration of MORE-DG Mice
Heterozygous floxed dystroglycan/null (L/) mice were bred to mice challenge was determined by counting 300 fibers randomly chosen
from 5–10 regions per toxin-challenged muscle in wild-type, MCK-hemizygous for Mox2 Cre transgene (MORE mice, Tallquist and
Cell
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DG null, mdx, and -sarcoglycan null mice (n  4). These data were Durbeej, M., Cohn, R.D., Moore, S.A., Hrstka, R.F., Allamand, V.,
Davidson, B.L., Williamson, R., and Campbell, K.P. (2000). Disruptionanalyzed statistically using Student’s t test.
of the -sarcoglycan gene reveals a complex pathogenetic mechan-
sim for LGMD 2E. Mol. Cell 5, 141–151.Irradiation of the Mouse Hind Limb
Mice were anesthetized with Ketamine and the hind limb irradiated Ervasti, J.M., Ohlendieck, K., Kahl, S.D., Gaver, M.G., and Campbell,
with a single dose of 18.0 or 25.0 Gy 137Cs  rays (J.L. Shepherd K.P. (1990). Deficiency of a glycoprotein component of the dys-
and Assoc., Glendale, CA, model 81-16 beam irradiator). Anesthe- trophin complex in dystrophic muscle. Nature 345, 315–319.
tized air-breathing mice were placed inside a purpose-built lead- Ferrari, G., Cusella-De Angelis, G., Coletta, M., Paolucci, E., Stornai-
lined irradiation jig with an opening that exposed the hind limb but uolo, A., Cossu, G., and Mavilio, F. (1998). Muscle regeneration by
shielded the remainder of the body. In those studies where both bone marrow-derived myogenic progenitors. Science 279, 1528–
hind limbs were irradiated with a dose of 18 Gy, each hind limb was 1530.
sequentially irradiated. The dose rate at a source-to-skin distance
Garry, D.J., Meeson, A., Elterman, J., Zhao, Y., Yang, P., Bassel-
of 15 cm was 2.66 Gy/min, measured using radiochromic film (Inter-
Duby, R., and Williams, R.S. (2000). Myogenic stem cell function is
national Specialty Products, Wayne, NJ, type HS prototype film).
impaired in mice lacking the forkhead/winged helix protein MNF.
Proc. Natl. Acad. Sci. USA 97, 5416–5421.
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